In a pathway basket trial, nine pancreatic cancer patients showing HER2 overexpression or gene amplification by using fluorescence in situ hybridization (FISH) were treated with the combination therapy of trastuzumab and pertuzumab, which is an HER dimerization inhibitor, and a 22.2% objective response rate was obtained [75]. Here, ERBB2 is linked to familial pancreatic carcinoma.